Recently, a first‐in‐class STAMP (specifically targeting the ABL myristoyl pocket) inhibitor, asciminib, was approved for treatment of patients with CML‐CP who exhibited resistance or intolerance to two prior TKI therapies [26]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.